Study S003271

A Phase 2, Double-blind Dose Escalation Regimen of Once-Weekly OPK-88003 in Subjects With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT03406377
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 113
Start: 2018-04-02
Primary completion: 2019-03-08
Lead sponsor: OPKO Health, Inc.
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:OPK-88003; DRUG:Placebo
Results posted: TRUE

Registered primary outcomes

Change in HbA1c in Subjects With Type 2 DM [From baseline to 30 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.